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Introduction: Drug-induced effects on the cardiovascular system remain a major cause of drug attrition. While
hemodynamic (blood pressure (BP) and heart rate (HR)) and electrophysiological methods have been used in
testing drug safety for years, animal models for assessing myocardial contractility are used less frequently and
their translation to humans has not been established. The goal of these studies was to determinewhether assess-
ment of contractility and hemodynamics, when measured across different laboratories using the same protocol,
could consistently detect drug-induced changes in the inotropic state of the heart using drugs known to have
clinically relevant positive and negative effects on myocardial contractility.
Methods: A 4 × 4 double Latin square design (n = 8) design using Beagle dogs was developed. Drugs were
administrated orally. Arterial blood pressure, left ventricular pressure (LVP) and the electrocardiogram were
assessed. Each of the six laboratories studied at least 2 drugs (one positive inotrope (pimobendan or amrinone)
and one negative inotrope) (itraconazole or atenolol) at 3 doses selected to match clinical exposure data and a
vehicle control. Animals were instrumented with an ITS telemetry system, DSI's D70-PCTP system or DSI's
Physiotel Digital system. Data acquisition and analysis systems were Ponemah, Notocord or EMKA.
Results:Derived parameters included: diastolic, systolic andmean arterial BP, peak systolic LVP, HR, end-diastolic
LVP, and LVdP/dtmax as the primary contractility index. Blood samples were drawn to conﬁrm drug exposures
predicted from independent pharmacokinetic studies. Across the laboratories, a consistent change in
LVdP/dtmax was captureddespite somedifferences in the absolute values of someof thehemodynamic parameters
prior to treatment.
Discussion: These ﬁndings indicate that this experimental model, using the chronically instrumented conscious
dog, can accurately and consistently detect changes in cardiac contractility, across multiple sites and instrumenta-
tion systems, and that data obtained in this model may also translate to clinical outcomes.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Washington, DC 20005, United
. This is an open access article under1. Introduction
Drugs can have a variety of effects on the cardiovascular system
including hemodynamic and electrophysiological effects. Given the
critically important physiological role of the cardiovascular system, inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Left ventricular pressure, itsﬁrst derivative (dP/dt) and thepeak value of dP/dt, (dP/dtmax). dP/dtmax occurs during systolic contractionwhen the rate of change inpressure over time
(slope of the curve) achieves its peak value. This time can be seen in the top tracewhere the instantaneous slope of a line tangent to the curve is the highest and in the bottom trace as the
peak positive value of dP/dt. (Modiﬁed from Sarazan, Kroehle & Main, with permission).
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fects, it has long been the subject of nonclinical testing. In 2001, cardio-
vascular safety assessmentwas included in a global regulatory guidance
for safety pharmacology testing (Anon., 2001). A fundamental property
of the cardiovascular system is the inotropic (or contractile) state of the
heart (these two terms will be used interchangeably in this manu-
script), which is a major determinant of cardiac output. The inotropic
state of the heart is under neurohumoral control to match the cardiac
output to the metabolic needs of the body. However, the inotropic
state of theheartmay be affected by disease and is also a potential target
for drug-induced effects, with direct inﬂuence on cardiac pump perfor-
mance and therefore cardiac output.
Both increases and decreases in the inotropic state of the heart may
be harmful, depending upon the patient population. Whereas a slight
change of the inotropic state of the heart may not compromise cardiac
output in a healthy individual, a patient with depressed cardiac pump
performance may be subject to an acute heart failure and dyspnea.
Alternatively, an increase in the inotropic state of the heart may not
be tolerated by a patientwith coronary artery disease since the resultant
increase in myocardial oxygen consumption, and therefore demand
for myocardial perfusion, may not be met, resulting in a mismatch in
oxygen demand and supply. Thus, it should be obvious that unwanted,
drug-induced alterations of the inotropic state of the heart can pose a
risk to patients.
Given the potential for drug-induced effects on the myocardial ino-
tropic state to be clinically relevant in susceptible patient populations,Table 1
Drugs tested in conscious telemetered dogs for effects on left ventricular contractility.
Test article Doses (oral) Formulation/veh
Pimobendan Vehicle, 0.1, 0.3 & 1 mg/kg PCCA Fixed Oil S
Amrinone Vehicle, 0.5, 2 & 5 mg/kg Dosed in gelatin
Itraconazole Vehicle, 3, 10 & 30 mg/kg 0.5% (w/w) met
polysorbate 80 a
Atenolol Vehicle, 0.3, 1 & 3 mg/kg Deionized water
Table 2
Study site characteristics and drugs tested in contractility assessments by participating compan
Participant No. of Beagle dogs Strain Source
AbbVie 8 Beagle Marshall
Amgen/Covance 8 Beagle Covance
Boehringer Ingelheim 8 Beagle Marshall
Data Sciences International (DSI) 8 Beagle Covance
Millennium 8 Beagle Marshall
Sanoﬁ 8 Beagle Harlanit is advisable to evaluate drugs for such effects when targeted for sus-
ceptible patients. While it seems surprising that examinations of the
inotropic effects of drugs are not a part of the core battery studies
outlined in the ICH S7A Guidance on Safety Pharmacology, in large
part this was due to the idea that ﬁrst in human studieswould primarily
be conducted in healthy subjects, and the core battery was put in place
to prepare for those studies. Additionally, at the time the guideline was
written, there was the perception that there was a lack of a practical ex-
perimental approach to test for such effects. Indeed, the assessment of
the inotropic state of the heart is fraught with challenges. Theoretically,
the preferred approach for making this assessment is based on the wall
stress versus strain relationship of the heart throughout the cardiac
cycle, which can be estimated using the relationship between the
ventricular pressure versus volume (Suga, Sagawa, & Shoukas, 1973).
The utility of this approach for routine drug testing is limited, however,
since the continuous measurement of ventricular volume over time,
particularly in conscious animals, is challenging. An alternative ap-
proach for assessing the inotropic state of the heart uses the maxi-
mal rate of pressure increase in the left ventricle during systole
(LVdP/dtmax). This parameter is experimentally accessible since it
only requires a high ﬁdelity left ventricular pressure signal, which can
be obtained through the use of a high ﬁdelity left ventricular pressure
transducer, and a high frequency differentiator (Fig. 1). Although this
index of myocardial contractility can be affected by changes in both
left ventricular preload and afterload, in addition to changes in inotropic
state (Hamlin & del Rio, 2012), studies have consistently demonstratedicle Cardiac inotropic effect
uspension Vehicle™ Positive
capsules Positive
hocel E50 in water containing 0.01% (w/w)
nd 10 mM phosphate buffer (pH 6.80–7.20)
Negative
Negative
ies (listed alphabetically).
Sex Telemetry system Software
Farms Male DSI Physiotel D70-PCTP Emka
Research Products Male DSI Physiotel D70-PCTP Ponemah
/Boehringer Ingelheim M/F Konigsberg (ITS) T27 Notocord
Research Products Male DSI Physiotel Digital L21 Ponemah
BioResources Male DSI Physiotel D70-PCTP EMKA
M/F DSI Physiotel D70-PCTP Notocord
Table 3
Super-intervals evaluated for each of the test compounds (in hours after dosing).
Itraconazole Amrinone Atenolol Pimobendan
0.5–3.6 0.5–3.5 0.5–5.5 0–6
5–6 5.0–6.5 8–12.17 8–13
8–13 8–13.5 12.17–16.5 13–18
13–18 13.5–19 20–24 20–24
20–24 20.5–24
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(Zimpfer & Vatner, 1981) and LVdP/dtmax is remarkably free from
effects of afterload (Maso, Braunwald, Covell, Sonnenblick, & Ross,
1971). Furthermore, acute, drug induced changes in preload or
afterload would be easily detected through changes in left ventricular
end diastolic pressure or systemic arterial pressure, respectively. LV
dP/dtmax is, however, highly dependent on heart rate, such that drug-
induced changes in heart rate will also affect LVdP/dtmax. Keeping in
mind LVdP/dtmax's potential use in drug testing, one would not antici-
pate such large changes in either preload, afterload or heart rate thatFig. 2. Effect of amrinone on LV dP/dtmax in conscious instrumented dogs at ﬁve different labor
orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. S
mean ± SE within each super-interval.could complicate the interpretation of drug-induced effects on this
index since large changes in these parameterswould per se pose serious
concerns of a given compound's suitability for development. Thus,
LVdP/dtmax may offer a useful parameter for detecting drug-induced
inotropic activity in the conscious animal.
The use of LVdP/dtmax as an index of cardiac contractility in drug
testing would be further supported if it could be shown to provide sim-
ilar data describing drug-induced effects across multiple laboratories
(Sarazan et al., 2011). The relationship between plasma drug concentra-
tion and its inotropic effect in the animal should also be similar to that
seen in humans, if themodel is to be useful in predicting risk to patients.
The ILSI Health and Environmental Sciences Institute (HESI) has
therefore organized a multi-center consortium with this goal in mind.
The participants have designed a double 4 × 4 Latin square study
(n = 8/site) using chronically instrumented Beagle dogs to assess
dose-dependent, drug-induced LV contractility changes after treatment
with drugs known to have clinically relevant positive (pimobendan and
amrinone) or negative (itraconazole and atenolol) inotropic effects
(Table 1). Additionally, arterial blood pressure (BP), LV pressure (LVP)
and ECG were collected using telemetry prior to dosing and overatories. Amrinone (vehicle = □, 0.5 mg/kg = ∇, 2 mg/kg= •, 5 mg/kg = Δ) administered
haded areas represent super-intervals as deﬁned in Table 3. Large symbols represent the
Fig. 3. Effect of pimobendan on LV dP/dtmax in conscious instrumented dogs at three different laboratories. Pimobendan (vehicle = □, 0.1 mg/kg = ∇, 0.3 mg/kg = •, 1 mg/kg = Δ) ad-
ministered orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large symbols rep-
resent the mean ± SE within each super-interval.
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dtmax, included peak systolic LVP, HR, systolic, diastolic andmean arteri-
al blood pressure, the Q-A interval (Norton, Iacono, & Vezina, 2009), left
ventricular end-diastolic pressure (LVEDP), dP/dtmin, and Tau (Weiss,
Frederiksen, & Weisfeldt, 1976). In this report, only the LVdP/dtmax pa-
rameterwill be included, whereas the other measures of systolic func-
tion (Q-A interval and dP/dt40) and lusitropic endpoints (dP/dtmin, and
Tau) will be dealt with in a subsequent report.
The data derived indicate that LVdP/dtmax is a robust, sensitive and
reliable parameter, useful for assessing both clinically relevant drug-
induced positive and negative inotropic effects. Despite differences in
baseline values, therewas good reproducibility of results across the par-
ticipating laboratories suggesting that it can be successfully applied
across laboratories despite these differences. Importantly, plasma drug
levels achieved in these studies were similar to those having clinically
relevant effects. This suggests a good translation of the effects from
the conscious dog model to effects seen in man, thereby supporting
the value of these studies in drug development.
2. Materials and methods
2.1. Test facilities
Studies were performed by 6 independent companies. Each of these
6 companies conducted the in-life phase of their study either withintheir own vivarium or outsourced to a contract research laboratory of
their own choosing (Table 2). Each individual study was therefore
subject to the local guidelines in terms of the vivarium conditions,
study conduct and animal use approval procedures. All participating
institutions (sponsors and contract laboratories, where used) havewar-
ranted strict adherence to all applicable animal use regulations in the
conduct of these studies. Although efforts were made to harmonize
testing procedures and conditions, the local animal use regulations
were always given priority when conﬂicts arose.
2.2. Experimental animals
All participating laboratories used purpose bred Beagle dogs ac-
quired from a vendor within their geographic region (North America
or Europe). Four laboratories used only male dogs and the other two
laboratories used both males and females. The strain, source and sex
of the dogs used by the various laboratories are summarized in Table 2.
Animals were either naïve at the study onset (one site) or they had
been used previously in safety pharmacology studies but were healthy
and free of any residual test article at the start of the study (remaining
5 sites). No animals were required to be euthanized in the context of
this study. After an appropriate recovery period following surgery or
washout period after receiving a drug, animals were subjected to a
standard clinical pathology examination to evaluate their health status
according to local procedures (typically including blood cell counts,
Fig. 4. Effect of atenolol on LV dP/dtmax in conscious instrumented dogs at three different laboratories. Atenolol (vehicle = □, 0.1 mg/kg= ∇, 0.3 mg/kg = •, 1 mg/kg= Δ) administered
orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large symbols represent the
mean ± SE within each super-interval.
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and liver function) and were qualiﬁed for use in further studies.
2.3. Telemetry instrumentation
Each participating laboratory used one of three commercially avail-
able implantable large animal telemetry systems; PhysioTel™ model
D70-PCTP (Data Sciences International, St. Paul, MN), PhysioTel™
Digital model L21 (Data Sciences International, St. Paul, MN), or ITS
model T27 (Konigsberg Instruments, Monrovia, CA). The system used
by each laboratory is identiﬁed in Table 2.
Regardless of the telemetry systemused, all dogswere instrumented
to monitor aortic blood pressure (BP), left ventricular pressure (LVP),
the electrocardiogram (ECG), body temperature and activity (note
that the temperature and activity endpoints were not evaluated in this
study).
2.4. Surgery
Dogs were instrumented with the implantable telemetry system
under general anesthesia using aseptic technique according to the pro-
cedures approved by the individual facility's animal welfare oversightcommittee (IACUC/OB) and appropriate to the type of telemetry system
being used. Postoperative analgesic, anti-inﬂammatory and antimicrobi-
al drugs were administered according to the institutions' approved pro-
cedures. All animals were allowed to fully recover from surgery prior to
study onset. In some cases, dogs were obtained from a preexisting colo-
ny of instrumented animals that had previously been used for other
pharmacology studies.
A general description of the surgical implantation procedure for each
telemetry system is described in the following sections:
2.4.1. Konigsberg (ITS) T27
The sites that used Konigsberg (ITS) telemetry systems all used
similar surgical procedures (Klumpp, Trautman, Markert, & Guth,
2006). The transducers of the T27 implant were calibrated and the
unit was sterilized using a low pressure ethylene oxide process prior
to implantation.
The anesthetized dogs were placed in right lateral recumbency. A
skin incision was made between the ﬁfth and sixth intercostal space. A
small pocket was opened in the abdominal wall for implantation of
the transmitter, battery housing, and induction switch coil. Both pres-
sure transducer wires and the ECG leads extending from the transmitter
were guided subcutaneously to the lateral incision. The initial incisions
Fig. 5. Effect of itraconazole on LV dP/dtmax in conscious instrumented dogs at four different laboratories. Itraconazole (vehicle =□, 3 mg/kg = ∇, 10 mg/kg = •, 30 mg/kg= Δ) admin-
istered orally at time= 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large symbols represent
the mean ± SE within each super-interval.
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racotomy was performed between the ﬁfth and sixth intercostal space
under intermittent positive pressure ventilation to expose the leftTable 4
Summary of the pharmacokinetics of the four drugs tested as determined in independent
studies.
Compound Dose (mg/kg) Tmax (hours) Cmax (ng/mL) AUC (ng ∗ hr/mL)
Amrinone 0.5 1.7 ± 0.5 269 ± 64 1247 ± 152
2 2.7 ± 1.0 743 ± 257 4448 ± 1265
5 2.5 ± 1.2 2652 ± 1096 13,795 ± 4264
Atenolol 0.3 1.3 ± 0.5 174 ± 53 997 ± 143
1 1.5 ± 0.5 538 ± 92 3333 ± 482
3 1.3 ± 0.5 1718 ± 364 9425 ± 1026
Itraconazole 3 2.5 ± 1.2 373 ± 92 6748 ± 1605
10 2.3 ± 0.8 1253 ± 222 23,083 ± 5184
30 2.7 ± 2.2 2127 ± 838 47,450 ± 13,794
Pimobendan 0.1 3.3 ± 1.0 1.9 ± 0.6 4.4 ± 1.6
0.3 3.2 ± 1.3 7.3 ± 2.7 22.5 ± 10.4
1 2.3 ± 1.4 22.9 ± 13.5 89.7 ± 17.8ventricular apex for insertion of the transducer, whichwas then secured
with a purse string suture.
A purse string suture was preplaced in the descending thoracic
aorta, the aorta was occluded with a vascular clamp and the pressure
transducer, which also served as the negative ECG electrode, was
inserted through a stab incision. The transducer was secured in place
by tightening the purse string suture and the vascular clamp was
removed, thus restoring blood ﬂow.
The lungwas then inﬂated and the intercostalmuscles were sutured
closed and the air was removed from the pleural space. The chest wall
was closed in layers and the skin was sutured.
After appropriate recovery period deﬁned by each participating
laboratory, animals were returned to the colony of implanted dogs in
group-housing conditions.
2.4.2. DSI Physiotel D70-PCTP & Physiotel Digital L21
Four of the laboratories using DSI telemetry implants (D70-PCTP
and L21) implanted the devices through an abdominal laparotomy
approach, whereas one laboratory (D70-PCTP) used an intercostal
thoracotomy approach.
Table 5
Average plasma drug concentrations (ng/mL) measured in each study at a single time
point to conﬁrm drug exposure. For oral doses used refer to Table 1.
Amrinone Low dose Mid dose High dose
Site 1 74 304 588
Site 2 NA NA NA
Site 3 122 485 1390
Site 5 135 621 1484
Site 6 92 402 1080
Average 106 453 1136
Pimobendan
Site 1 0.505 1.08 10.0
Site 2 0.205 0.582 1.771
Site 4 0.195 0.65 1.825
Average 0.317 0.77 4.53
Atenolol
Site 1 251 639 1409
Site 2 NA 320 1114
Site 5 112 389 1221
Average 182 449 1248
Itraconazole
Site 1 199 877 1760
Site 3 316 908 2230
Site 4 267 722 1730
Site 6 220 832 2250
Average 251 835 1993
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was similar across all sites and device models. Differences included:
1) placement of the implant body either within the peritoneal cavity
or in a pocket between the peritoneum and the abdominal muscles,
2) the L21 implant has a short external antenna that was routed
between the peritoneum and the abdominal muscles, whereas the
D70-PCTP's antenna is internal, and 3) some blood pressure sensor can-
nulae were inserted into a femoral artery and others were inserted into
a branch of the mesenteric artery that perfuses the jejunum. In both
cases, the artery or arterial branch was ligated and the sensor tip was
advanced into the abdominal aorta. The implants arrived precalibrated
and sterile from the manufacturer.
The abdomen was approached via a longitudinal incision along the
linea alba. The arterial sensor was routed either through the abdominal
wall to the inguinal region where the femoral artery was exposed or
directly into one of the arcuate branches of a jejunal mesenteric artery.
Under intermittent positive pressure ventilation a dorso-ventral inci-
sion was made in the diaphragm from the abdominal side, the pericar-
dium was opened, and the left ventricular apex of the heart was
exposed. A non-absorbable suture was placed around the suture aid
near the tip of the pressure transmission catheter and tied. Another
non-absorbable suture was placed around the left ventricular apex in
a purse string pattern. The LV apex was perforated with a hypodermic
needle, the hole was dilated slightly with a straight Kelly forceps and
the pressure sensing tip of the catheterwas advanced into the LV cham-
ber. After conﬁrmation of a normal LVP signal on the computermonitor,
the purse string suture was tightened and tied using traditional surgical
knot tying technique. The tails of the suture that was previously tied
around the catheter suture aid were then tied to the tails of the purse
string to ensure the sensor could not back out of the ventricle.
The diaphragmatic incision was closed with braided absorbable
suture in a continuous pattern. The lungs were gently inﬂated and the
air was removed from the pleural spacewith a ﬂexible catheter inserted
between the continuous diaphragmatic sutures. The abdominal incision
was closed in layers and the skin was closed with either continuous,
subcuticular absorbable sutures, skin sutures or skin staples.
For the site that used the thoracotomy approachwith the DSI device,
the surgery was similar to that described previously (Henriques et al.,
2010). Differences at other sites include the placement of one of the
ECG electrodes on the left auricle of the heart and the second insidethe thorax on a rib near the apex of the heart. Also, the systemic arterial
pressure catheter was routed to the femoral artery and inserted up into
the abdominal aorta.
2.5. Drugs tested
Four drugswere studied, each a knownpositive or negative inotropic
drug in humans when given at clinical doses. Not all test articles were
studied in each laboratory (Table 2). The doses and formulations used
are described in Table 1.
2.6. Study design
Four different treatments were administered to each dog in the
order prescribed by a double 4 × 4 Latin square design (n = 8) over
four treatment days, with an appropriate washout period between
days. A 4 × 4 Latin square contains four rows and four columns. The
four treatments are randomly assigned to experimental units within
the rows (days) and columns (animals) so that each treatment appears
in every row and in every column. A double 4 × 4 Latin square is a com-
bination of two identical 4 × 4 Latin squares, resulting 4 rows and 8 col-
umns. The design is particularly appropriate for comparing four
treatmentmeans in the presence of two sources of extraneous variation.
The washout period was a minimum of 72 h between treatment days.
Foodwaswithdrawn approximately 2 h before dosing in themorning
and reintroduced in the afternoon, which was well after the anticipated
tmax of the tested drug.
2.7. Pharmacokinetic proﬁles and exposure conﬁrmation
A full pharmacokinetic proﬁle of all four test compounds using the
doses selected was determined by two of the participating companies.
These data were used to deﬁne Cmax/tmax as well as to deﬁne the time
point at which all studies included a single plasma sampling to conﬁrm
drug exposure in each animal, on each study day. The plasma samples
were then frozen and, at the conclusion of the studies bioanalytical
measurements were performed.
2.8. Data collection and analysis
2.8.1. Raw data (signals)
Digital cardiac left ventricular pressure (LVP), aortic blood pressure
(BP), and electrocardiogram (ECG) signals were continuously acquired
from at least 1 h prior to dosing through 24 h post-dose on each study
day. In some cases body temperature and activity signals were also
acquired. Sampling rates were ≥500 Hz for LVP and ECG signals,
≥250 Hz for BP signals and ≥20 Hz for temperature and activity signals,
which is adequate for the frequency content of each of these signal types
(Sarazan, 2014; Sarazan, Kroehle, & Main, 2012). Digital raw data ﬁles
were archived to electronic media and retained at each individual
study site for future analysis as agreed upon within the HESI Cardiac
Safety Technical Committee.
2.8.2. Derived data (parameters)
A variety of derived parameters was calculated by the data analysis
software at each study site and included: heart rate, diastolic aortic
pressure, systolic aortic pressure, mean aortic pressure, pulse pressure,
left ventricular end-diastolic pressure, peak systolic left ventricular
pressure, dP/dtmax, dP/dtmin, dP/dt40, Tau (or the left ventricular diastolic
time constant) and the Q-A interval (or systolic time interval between
the Q wave and the onset of the aortic blood pressure pulse). Although
a large number of parameters were available, this manuscript is limited
to cardiac function and to hemodynamic parameters that are directly or
indirectly relevant to the evaluation of cardiac contractility.
Fig. 6. Effect of amrinone on heart rate in conscious instrumented dogs at ﬁve different laboratories. Amrinone (vehicle = □, 0.5 mg/kg = ∇, 2 mg/kg = •, 5 mg/kg = Δ) administered
orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large symbols represent the
mean ± SE within each super-interval.
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Although derived data were calculated for every cardiac cycle, the
results were collapsed into 10-minute mean values for further analysis.
Thesemean values were further averaged to construct the pre-speciﬁed
super-intervals (Sivarajah et al., 2010) for each test article as shown in
Table 3. The super-intervals used for each compound were deﬁned by
a data evaluation subteam prior to the statistical analysis. The selection
was intended to avoid disturbances associated with dosing, changes
in light cycle or at the time of blood sampling for exposure conﬁrma-
tion. Each compound was treated individually, selecting intervals from
the average of LVdP/dtmax across the laboratories that tested a given
compound.
The effect of each test article on each of the cardiac parameters was
evaluated using a repeated measures analysis of covariance (Chiang,
Smith, Main, & Sarazan, 2004). Factors in the model included study
day, animal, treatment group, time after dose, (pretreatment) baseline,
and the interaction of time after dose with each of the other factors.
The within- and between-animal variability was modeled to follow a
compound symmetric structure (Chiang et al., 2007). The effects of
treatment and treatment by time interaction were tested by overallF-tests at the 0.01 signiﬁcance level. Monotonicity of dose response for
each super-interval was examined using sequential linear trend tests
at the 0.05 signiﬁcance level. Nonmonotonic dose responses were in-
vestigated whenever no signiﬁcant linear trends were detected but
therewas a signiﬁcant overall F-test for either the treatmentmain effect
or treatment by time interaction. The mean of each treatment group
was compared to that of the vehicle group using Bonferroni adjusted
t-tests at the 0.05 signiﬁcance level.
3. Results
The primary goal of this study was to assess whether multiple labo-
ratories, using similar but not identical state-of-the-art approaches for
measuring cardiovascular function in the conscious dog, were capable
of producing similar experimental results on the inotropic effects of
the compounds tested. The parameter LVdP/dtmax was selected to be
the most promising for this purpose and those results are presented in
this ﬁrst manuscript. A second, but important factor to interpret results
relates to the relationship of the observed effect onmyocardial contrac-
tility to the plasma drug levels of the compounds tested. This is
Fig. 7. Effect of pimobendan on heart rate in conscious instrumented dogs at three different laboratories. Pimobendan (vehicle=□, 0.1 mg/kg= ∇, 0.3 mg/kg= •, 1 mg/kg= Δ) admin-
istered orally at time= 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large symbols represent
the mean ± SE within each super-interval.
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drug level) and PD (effect on inotropic state) in the dog model used in
this study, in comparison to the PK/PD relationship found with clinical
use of the drugs, as reported in the literature. As mentioned above, the
parameter LVdP/dtmax can be inﬂuenced by changes in heart rate or
either preload or afterload of the left ventricle. The parameters mea-
sured in these studies that reﬂect these potential changes, due to their
effect on LVdP/dtmax, were also examined.
3.1. Effects of the test compounds on LVdP/dtmax across laboratories
Studies using amrinone were conducted in 5 different laboratories,
atenolol and pimobendan were each tested in 3 laboratories and
itraconazole was tested in 4 different laboratories. The dose- and time-
dependent effects of the four test compounds on LVdP/dtmax, as detected
in each laboratory, are summarized in Figs. 2–5, respectively.
3.2. Positive inotropic drugs
3.2.1. Amrinone
All ﬁve laboratories that tested amrinone (Fig. 2) detected a dose-
dependent and reversible increase in LVdP/dtmax following both themid (2 mg/kg) and high (5 mg/kg) doses. None of the laboratories
found an effect on LVdP/dtmax with the low dose of 0.5 mg/kg. A slight
difference was seen between labs with regards to the duration of the
effect, with effects being seen in all labs during both the ﬁrst and second
super-intervals post-dosing with the high dose, but with increases
following the mid dose not lasting into the second superinterval in all
labs. One of the labs observed signiﬁcant increases in LVdP/dtmax follow-
ing the high dose even into the 3rd superinterval (8–13.5 h post-
dosing).
It was noted that the absolute values of LVdP/dtmax prior to adminis-
tration were variable amongst the laboratories, ranging from 2885 to
5142 mm Hg/s (Fig. 2). This different baseline level appeared to have
no effect on the sensitivity of the model to detect the drug-induced
increase, however.3.2.2. Pimobendan
The three laboratories that tested pimobendan found a dose-
dependent and reversible increase in LVdP/dtmax following both the
mid (0.3 mg/kg) and the high doses (1.0 mg/kg) (Fig. 3). With the low
dose there was no signiﬁcant effect on LVdP/dtmax in any of the three
studies. The increase in LVdP/dtmax was long-lasting, being signiﬁcant
Fig. 8. Effect of atenolol on heart rate in conscious instrumented dogs at three different laboratories. Atenolol (vehicle = □, 0.1 mg/kg = ∇, 0.3 mg/kg = •, 1 mg/kg = Δ) administered
orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large symbols represent the
mean ± SE within each super-interval.
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studies (site 2).
It was once again noted that differences in baseline values for
LVdP/dtmax had no apparent impact on the ability of themodel to detect
the drug-induced effects. Also, the absolute magnitude of the increase in
LVdP/dtmax was similar in two of the laboratories (sites 1 and 4), but less
in the third (site 2).3.3. Negative inotropic drugs
3.3.1. Atenolol
Three laboratories studied the effect of atenolol with two of them
ﬁnding a signiﬁcant decrease in LVdP/dtmax with all three doses tested
(0.3, 1, and 3 mg/kg) and for all of the 4 super-intervals deﬁned
(Fig. 4). The third laboratory did not detect a signiﬁcant decrease in
LVdP/dtmax with the lowest dose, during any of the super-intervals, de-
spite the fact that the mean values of LVdP/dtmax following treatment
were consistently below the baseline values particularly in the ﬁrst
super interval (0.5–5.5 h post-dosing).3.3.2. Itraconazole
Itraconazole was examined in four different laboratories and the
results are summarized in Fig. 5. All four laboratories detected a dose-
dependent and reversible decrease in LVdP/dtmax, most markedly with
the high dose of 30 mg/kg, but also with the mid dose of 10 mg/kg in
some cases. None of the labs detected an effect on LVdP/dtmax with
the lowdose of 3mg/kg. The effectwas long-lasting but returned largely
to control values by 24 h post-dosing, although slight effects still
persisted at two labs (site 1 and site 4).
3.4. Plasma drug levels
The four test compounds were tested in dedicated pharmacokinetic
studies prior to the main studies to determine the concentration-time
relationship of each compound after each dose administered orally to
Beagle dogs. This information was used to deﬁne the time of drawing
blood for exposure conﬁrmation in themain studies, aswell as for deﬁn-
ing the super-intervals for the statistical evaluation of the data. The
summary data from these 4 pharmacokinetic studies are summarized
in Table 4.
Fig. 9. Effect of itraconazole on heart rate in conscious instrumented dogs at four different laboratories. Itraconazole (vehicle = □, 3 mg/kg = ∇, 10 mg/kg = •, 30 mg/kg = Δ) admin-
istered orally at time= 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large symbols represent
the mean ± SE within each super-interval.
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3.5.1. Amrinone
When given in oral doses of 0.5, 2 or 5mg/kg, amrinone lead to peak
plasma levels (Cmax) of 269, 743 and 2652 ng/mL, respectively (Table 4).
The time of themaximal plasma concentration (Tmax) was similar rang-
ing from 1.7 to 2.7 h post-dosing.
3.5.2. Pimobendan
Pimobendan was tested using oral doses of 0.1, 0.3 and 1.0 mg/kg.
The resulting Cmax levels were 1.9, 7.3 and 22.9 ng/mL occurring at
Tmax of 3.3, 3.2 and 2.3 h post-dosing, respectively (Table 4).
3.6. Negative inotropic drugs
3.6.1. Atenolol
Oral doses of atenolol were 0.3, 1 and 3mg/kg and led to Cmax values
of 174, 538 and 1718 ng/mL occurring at Tmax values of between 1.3 and
1.5 h post-dosing (Table 4).3.6.2. Itraconazole
Doses for itraconazole were 3, 10 and 30 mg/kg given orally and
these were associated with Cmax values of 373, 1253 and 2127 ng/mL,
respectively (Table 4). The Tmax values were between 2.3 and 2.7 h
post-doing.
Inmost studies, plasma sampleswere drawn at a single time point to
conﬁrm that animals in the study had drug exposures in the anticipated
range based on the preliminary pharmacokinetic studies. These data are
summarized in Table 5 and conﬁrm the expected exposure, as well as a
good consistency of exposures across laboratories. It should be kept in
mind, however, that the exposure data do not represent maximal drug
concentrations as determined in the pharmacokinetic studies, as the
timing of the blood drawwas speciﬁed to be after Tmax to avoid artifacts
in the hemodynamic parameters at the time of maximal plasma levels.3.7. Hemodynamic parameters affecting LVdP/dtmax
The primary parameter used to assess myocardial contractility
in this study was LVdP/dtmax, a parameter known to be inﬂuenced
Fig. 10. Effect of amrinone on diastolic arterial blood pressure in conscious instrumented dogs at ﬁve different laboratories. Amrinone (vehicle = □, 0.5 mg/kg = ∇, 2 mg/kg = •,
5 mg/kg = Δ) administered orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3.
Large symbols represent the mean ± SE within each super-interval.
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LVEDP) and ventricular afterload (estimated using diastolic arterial
pressure). The effect of the four test articles on these parameters is sum-
marized here.3.8. Positive inotropic drugs
3.8.1. Amrinone
The effect of amrinone on heart rate was not uniform across the ﬁve
labs that tested it (Fig. 6). In three, there was no effect on heart rate at
any dose or any time following administrations. In two laboratories,
therewas an increase in heart rate restricted only to the high dose treat-
ment group and seen only in the ﬁrst or second superinterval, thereby
being transient in nature. In the three labs not ﬁnding a heart rate effect,
there was a decrease in diastolic arterial blood pressure with the high
dose (also with the mid dose in one lab), whereas it was unchanged
in the two labs having the heart rate increase (Fig. 10). In only one
of the labs, a decrease in LVEDP was seen following the high dose
(Fig. 14). In all other labs, no effects on LVEDP were noted.3.8.2. Pimobendan
Pimobendan administration was associated with only minor hemo-
dynamic effects. Heart rate was not affected in two of three labs, with a
slight increase following the high dose in one lab (Fig. 7). With the high
dose therewas also a small decrease in diastolic arterial pressure, which
was also seenwith themid dose in one lab (Fig. 11). LVEDPwas reduced
in two labs with both mid and high doses during the ﬁrst and second
super-intervals, in one lab no signiﬁcant effect was detected (Fig. 15).3.9. Negative inotropic drugs
3.9.1. Atenolol
The hemodynamic response to atenolol was generally mild. None of
the laboratories detected an effect on the LVEDP at any time or dose
(Fig. 16). Two of three labs also found no effect on heart rate, whereas
one found a signiﬁcant decrease with each of the three doses tested
(Fig. 8). Systemic diastolic arterial blood pressurewas reduced following
the mid and high doses in two of the studies but was unchanged in the
third (Fig. 12).
Fig. 11. Effect of pimobendan on diastolic arterial blood pressure in conscious instrumented dogs at three different laboratories. Pimobendan (vehicle=□, 0.1 mg/kg=∇, 0.3 mg/kg= •,
1 mg/kg=Δ) administered orally at time=0. Small symbols represent themean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large
symbols represent the mean ± SE within each super-interval.
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Itraconazole had little effect on LVEDP in all of the four studies
(Fig. 17). Systemic diastolic arterial pressure was either not affected,
or onlymildly increasing in one study and decreasing in another follow-
ing the high dose (Fig. 13). Heart rate tended to also be unchanged
although one study had an increase following only the high dose (Fig. 9).4. Discussion
The purpose of this study was to determine if a commonly used
conscious dogmodel is capable of detecting changes inmyocardial con-
tractility when used for assessing drug-induced effects on the cardio-
vascular system. This consortium was proposed based on the results
from a HESI supported workshop aimed to identify issues and opportu-
nities for improving our preclinical cardiovascular proﬁling of new
drugs (Sarazanet al., 2011). A recommendation coming from thatwork-
shop was that drug-induced effects on myocardial contractility should
be evaluated routinely and it was suggested that non-clinical models
are available to conduct such assessments. However, up to now the ro-
bustness of such models was never objectively evaluated, particularlyincluding the potential for cross-laboratory variability. The present
study has demonstrated that very similar experimental results could be
obtained from the different laboratories participating in this consortium.
All labs correctly categorized their assigned test compounds as being ei-
ther a positive or negative inotropic agent at the doses tested. Moreover,
the effectswere consistently shown tobedose-dependent and reversible,
further demonstrating the comparability of the effects detected.
A second issue of interest, with regards to the translation of such
preclinical data to the clinic, involves the doses, or more importantly
the achieved plasma drug concentrations, associated with a given effect
on myocardial contractility, i.e., PK/PD. In the best case, the preclinical
model should respond to the drug-induced effect on contractility at
drug concentrations similar to those known to have similar effects in
the clinical setting. Clearly, if the preclinical models are less sensitive
to the clinical setting, onemight eithermiss or underestimate the impor-
tance of an effect. Conversely, should the preclinical model be more sen-
sitive to the effects thanwhat is seen clinically, themodelmay incorrectly
overestimate the risk for clinically relevant effects and could therefore
lead erroneously to the discontinuation of the development of a safe
drug. As mentioned below for the individual drugs tested, the relation-
ship between the drug concentrations shown to cause dose-dependent
Fig. 12. Effect of atenolol on diastolic arterial blood pressure in conscious instrumented dogs at three different laboratories. Atenolol (vehicle = □, 0.1 mg/kg = ∇, 0.3 mg/kg = •,
1 mg/kg = Δ) administered orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3.
Large symbols represent the mean ± SE within each super-interval.
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erature data on doses and plasma drug concentrations found to cause
the effects clinically. One must acknowledge the difﬁculty in com-
paring preclinical and clinical data to the inherent difference be-
tween these study types and the types of measurements used.
Nevertheless, the correlation between the effect on myocardial con-
tractility to drug concentration in both preclinical and clinical set-
tings appears to be quite good. This underscores the importance of
including measurements of plasma drug levels in preclinical studies.
Whereas taking blood samples in the conscious animals is associated
with a temporary disturbance of the hemodynamic measurements
being made, in well-trained animals the effects are brief and quickly
reversible. Furthermore, use of super-intervals in the data evaluation
(see below) can be used effectively to eliminate transient artifacts in
the data set by simply excluding times during which the animals are
excited due to either feeding or the drawing of blood. Given the impor-
tance of the measurement of drug levels for the interpretation of the
data, taking a single blood sample at some time shortly after the expect-
ed tmax appears to be a good compromise.A further area of concern in this consortium study was the selection
of LVdP/dtmax as the primary index of contractile function. From theo-
retical considerations, based on the possible inﬂuences of ventricular
preload and afterload on the assessment parameter, looking for changes
in inotropic state by using the pressure–volume relationship through-
out the cardiac cycle may be preferable (Suga et al., 1973). Its use in
the conscious, freely moving dog is technically less feasible, such that
the consortium selected the more commonly used and more accessible
parameter of LVdP/dtmax, the maximal rate of pressure development in
the left ventricle during systole. It was proposed that large changes in
heart rate and ventricular preload or afterload that could potentially af-
fect the use of LVdP/dtmax as a contractility index, would not be expect-
ed in the context of a drug development, as such large effects would be
viewed critically, independently from possible changes in myocardial
contractility. Furthermore, with the continuous measurement of heart
rate, left ventricular pressure and arterial blood pressure, the experi-
mental model monitors the parameters that can have an impact on
LVdP/dtmax. Thus, changes in LVdP/dtmax devoid of relevant changes in
these parameters can be assumed to reﬂect real, drug-induced changes
Fig. 13. Effect of itraconazole on diastolic arterial blood pressure in conscious instrumented dogs at four different laboratories. Itraconazole (vehicle = □, 3 mg/kg = ∇, 10 mg/kg = •,
30 mg/kg = Δ) administered orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3.
Large symbols represent the mean ± SE within each super-interval.
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four test compounds on heart rate, end-diastolic left ventricular pressure
andmean arterial pressurewere, in fact,minimal. Onlywith pimobendan
was there a consistent effect on LVEDP, the effect being a decrease follow-
ing themid and high dose in two of three labs. Since a decrease in LVEDP
would lead to a decrease in LVdP/dtmax, based upon the Cyon–Frank–
Starling effect (see Zimmer, 2001), this obviously did not have a relevant
impact on the observed increase in LVdP/dtmax. Diastolic aortic pressure
was found to be reduced in 3 of 5 labs testing amrinone, an effect seen
primarily with the high dose. Such a decrease would be expected to re-
duce LVdP/dtmax and would counteract the observed increase in LVdP/
dtmax indicating that this change was not relevant for the detection of
the positive inotropic effect. Slight reduction in diastolic aortic pressure
was found with pimobendan (all three labs) as well as with atenolol (2
of three labs with both mid and high doses). As with amrinone, the ob-
served decrease in diastolic aortic pressure would tend to minimize the
observed increase in LVdP/dtmax and can be interpreted to have little rel-
evance for the inotropic assessment. The decrease in diastolic aortic pres-
sure observed with atenolol is likely a result of the negative inotropiceffect, but it must be recognized that it could also play a role in the re-
duced LVdP/dtmax as well.
LVdP/dtmax is dependent on heart rate, being based physiologically
on the force–frequency relationship of the heart (Markert et al., 2007)
and is therefore a further source of potential error when using this
parameter to assess changes in contractile state of the heart. Except
for slight increases in heart rate with the highest doses of amrinone
and pimobendan tested, most compounds and doses were not asso-
ciated with marked changes in the heart rate suggesting that the
LVdP/dtmax is correctly reﬂecting changes in myocardial contractility.
With amrinone, 2 of 5 labs observed an increase in heart rate following
the high dose, meaning that part of the observed increase in LVdP/dtmax
may be heart rate-dependent. Taken together, the changes observed
with drug administration on parameters reﬂecting the preload and
afterload of the left ventricle were modest and in some cases would
have minimized the change in LVdP/dtmax anticipated for the inotropic
change. Thus, the results of this study support the use of LVdP/dtmax as
an index of left ventricular contractility in the context of testing for
cardiovascular effects of drug candidates.
Fig. 14. Effect of amrinone on left ventricular end-diastolic pressure in conscious instrumented dogs at ﬁve different laboratories. Amrinone (vehicle = □, 0.5 mg/kg = ∇, 2 mg/kg = •,
5 mg/kg = Δ) administered orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large
symbols represent the mean ± SE within each super-interval.
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induced effects on the inotropic state of the heart. Indeed, in the context
of this consortium study, several other parameters were evaluated that
may have value in detecting and quantifying changes in myocardial
contractility. Some are based on hemodynamic data, whereas others
employ different technologies, such as echocardiography. A comparison
of these other approaches, in comparison to the results of the present
study will be the subject of subsequent publications.
Themembers of the consortium selected four compounds to be used
in this study, two expected to have a positive inotropic effect based on
clinical experience with the drug and two expected to have a negative
inotropic effect. Preference was given to drugs that were thought
to have rather selective effects on myocardial contractility without si-
multaneous effects on arterial blood pressure or heart rate to reduce
the role of secondary effects in the assessment. This goal was achieved
overall, as discussed above. A further consideration was the avail-
ability of clinical data demonstrating the relationship of the inotropic
effect to dose or plasma drug levels, to allow for a comparison of
the data generated in the present study. Ultimately, pimobendan andamrinone were selected as the two positive inotropic agents and aten-
olol and itraconazole were selected as the negative inotropic agents.
In the present study using the chronically instrumented Beagle dog,
all participating laboratories were able to demonstrate the anticipated
effect on LVdP/dtmax of the compounds tested, thereby classifying
them correctly as either positive or negative inotropic agents. The
compound-induced effects observed could furthermore be shown to
be dose-dependent and reversible, two characteristics that also support
the conclusion that the effects seen were drug-dependent. Efforts were
made to eliminate methodological differences between the participat-
ing laboratories, but some differences that may have affected the
outcome remained. Nevertheless, the overall results between laborato-
ries were very similar, particularly when drug-induced effects were
assessed as a change from the respective baseline values (see below
for more discussion). Furthermore, the plasma concentrations found
to produce positive or negative inotropic effects in the dog were very
similar to the plasma drug concentrations known to be inotropic in
man. At least based on these four drugs, there seems to be an excellent
correlation between the exposure–response relationship in the dog as
Fig. 15. Effect of pimobendan on ventricular end-diastolic pressure in conscious instrumented dogs at three different laboratories. Pimobendan (vehicle=□, 0.1mg/kg=∇, 0.3mg/kg=
•, 1mg/kg=Δ) administered orally at time=0. Small symbols represent themean value from theprevious 10-minutes. Shadedareas represent super-intervals as deﬁned in Table 3. Large
symbols represent the mean ± SE within each super-interval.
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studies appears well suited for testing new drugs for potential inotropic
effects.
4.1. Amrinone
Amrinone is a bipyridine phosphodiesterase III inhibitor known to
increase myocardial contractility and to be a vasodilator (Alousi &
Johnson, 1986). It is used for short-term treatment of severe heart
failure based on its positive inotropic action as well as its reduction of
arterial blood pressure (afterload), both effects leading to an increase
in cardiac output. In the present dog study, the oral doses of 0.5, 2 and
5 mg/kg produced modest, dose-dependent increases in LVdP/dtmax.
In the pharmacokinetic study conducted in the healthy Beagle dog, the
maximal plasma concentrations of amrinone following the three
oral doses used in this study were 269, 743 and 2652 ng/mL. In man,
amrinone has been reported to have a positive effect on left ventricular
function at a plasma concentration of 1200 ng/mL (Kullberg, Freeman,
Biddlecome, Alousi, & Edleson, 1981; Ward, Brogden, Heel, Speight, &
Avery, 1983) thereby being similar to the mid and high doses used in
the present study; supporting a good correlation between the plasmadrug levels causing an increase inmyocardial contractility in the healthy
dog versus that in man.
4.2. Pimobendan
Pimobendanwas an interesting compound for this study, as it causes
a rather selective positive inotropic action on the heart with little effect
on heart rate, at least in lower doses. It was developed clinically for the
treatment of heart failure but reached the market only in Japan (Kato,
1997). Nevertheless, it is a mainstay for the treatment of heart failure in
veterinary medicine, most notably in dogs (Atkins, Bonagura, Ettinger,
et al., 2009). Its positive inotropic action is described to be due to both
its phosphodiesterase III inhibition aswell as its calcium sensitizing prop-
erties (Van Meel & Diederen, 1989). Pimobendan was shown to have a
positive inotropic effect in healthy volunteers using echocardiography
when treated with an oral dose of 7.5 mg (Chu, Hu, & Shieh, 1999).
Fractional shortening was increased by 46% and ejection fraction was in-
creased by 29.8% with a maximal plasma concentration (total of both
enantiomeres) of about 13 ng/mL. It should be noted that in this study
with the oral dose of 7.5 mg there was also a signiﬁcant increase in
heart rate (38%) suggesting that this dose was larger than that needed
Fig. 16. Effect of atenolol on ventricular end-diastolic pressure in conscious instrumented dogs at three different laboratories. Atenolol (vehicle = □, 0.1 mg/kg = ∇, 0.3 mg/kg = •,
1 mg/kg = Δ) administered orally at time = 0. Small symbols represent the mean value from the previous 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3.
Large symbols represent the mean ± SE within each super-interval.
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study, a dose-dependent increase of LVdP/dtmax was observed across
laboratories starting with the low dose of 0.1 mg/kg and increasing
dose-dependently up to the high dose of 1 mg/kg which was associated
with a Cmax of 22.9 ng/mL in the independent pharmacokinetic study.
With the high dose used in the dog, there was also an increase in heart
rate. Thus, the plasma concentrations of pimobendan shown to be posi-
tive inotropic in the healthy Beagle dog correspond very well to the
plasma drug levels shown to be positive inotropic in the healthy human
volunteer.
4.3. Atenolol
As a selective cardiac ß1-adrenoceptor blocker, atenolol is expected
to reduce myocardial contractility and heart rate, particularly in hearts
under ß-adrenoceptor activation through neural or humoral stimula-
tion. It is widely used clinically for the treatment of hypertension, angina
and certain arrhythmias. It was shown to produce negative inotropic ef-
fects in the human heart at plasma concentrations of 330 ng/mL
(de Abreu, de Castro, & Pedrazzoli, 2003; Thomas et al., 1992). In the
present dog study oral doses of 0.3, 1 or 3 mg/kg were tested and
found to reduce LVdP/dtmax dose-dependently. In the independentpharmacokinetic study conducted in the Beagle dog, the Cmax values
for these three oral doses of atenolol were 174, 538 and 1718 ng/mL,
respectively, demonstrating a very similar range of plasma drug concen-
trations to those known to cause negative inotropic effects in man.
4.4. Itraconazole
Itraconazole (Sporanox®) is a synthetic triazole antifungal agent
that was selected for this study on the basis of its causing negative ino-
tropic effects with its clinical use, which ultimately led to a boxedwarn-
ing in its prescribing information. It has been shown to be associated
with heart failure with its clinical use, despite its negative inotropic ac-
tivity going undetected in both preclinical and clinical trials (Slordal &
Spigset, 2006). As such, it is a prime candidate for use in this study, pos-
ing the question whether or not the use of this experimental model
would have detected this effect, had such studies been performed
during the development of the compound. It has been reported that
itraconazole has a negative effect onmyocardial contractility in humans
at plasma drug concentrations of about 1000 ng/mL (Ahmad, Singer, &
Leiss, 2001; Hardin et al., 1988). In the pharmacokinetic study conducted
as a part of the present evaluation in Beagle dogs, the oral doses of
itraconazole used (3, 10 and 30 mg/kg) produced Cmax values of 373,
Fig. 17. Effect of itraconazole on ventricular end-diastolic pressure in conscious instrumented dogs at four different laboratories. Itraconazole (vehicle = □, 3 mg/kg = ∇, 10 mg/kg = •,
30mg/kg=Δ) administered orally at time=0. Small symbols represent themean value from theprevious 10-minutes. Shaded areas represent super-intervals as deﬁned in Table 3. Large
symbols represent the mean ± SE within each super-interval.
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and high doses (30 mg/kg) should have been associated with a negative
inotropic effect, provided that there is a good correlation between the
clinical observations and those in dogs. In fact, the mid and high doses
of itraconazole in this study decreased inotropy in the dog at similar
plasma concentrations to those detected in man.
Taken together, with all four test compounds there seems to be a
remarkably good correlation between plasma drug concentrations
found to affect LVdP/dtmax and those reported to cause inotropic effects
in man.
Qu et al. (2013) have recently published a study aimed to deﬁne the
mechanism of action for the negative inotropic effects of itraconazole
(Qu et al., 2013). Despite testing itraconazole in a variety of both
in vitro and in vivo models, these investigators could not determine
the responsible mechanism of action. They did manage to demonstrate
that it is a direct effect on the heart since it can be seen in isolated heart
preparations, and they have eliminated L-type Ca++ blockade or
involvement of the mitochondria as possible mechanisms.
The data generated in these dog studies demonstrate that the con-
scious dog model can detect both positive and negative inotropicactivity. The conscious dog is already one of the most commonly used
experimentalmodels for testing drugs for their potential cardiovascular
effects. The addition of a highﬁdelitymicromanometer into the left ven-
tricle of this animal species in this model allows for the detection of ino-
tropic effects in addition to heart rate, arterial blood pressure and the
ECG. Despite the best efforts of the participants, it was not possible to
harmonize all aspects of the study design in order to conduct similarly.
Nevertheless, the comparability of the overall outcomes is noteworthy.
Some differences between the participating sites were noted, however.
In particular, the baseline values of some of the parameters measured
were not uniform. This is perhaps best illustrated by the baseline heart
rate values reported, that ranged between studies across laboratories
testing amrinone and from a low, group baseline value of 85.6 beats
per minute to a high, group baseline value of 133.3 beats per minute.
Whereas environmental factors can inﬂuence the baseline hemodynamic
values obtained, it was also reported that the dogs having the high HR
values at baseline were relatively young and had been recently instru-
mented. As such, they were less acclimatized to the study environment
andwere likelymore excitable than in older,more thoroughly trained an-
imals used in some of the other laboratories. It should be emphasized,
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inotropic state, as assessed using LVdP/dtmax calculated as a change
from the baseline and compared to treatment with the vehicle, could be
clearly demonstrated in all laboratories, independently from their base-
line levels.
4.5. Data evaluation
A plot of the mean values of each parameter measured over time,
using short (e.g. 5min) intervals to average the data, provides a valuable
overviewof possible drug-induced effects. At a glance one can assess the
dose-dependency of any effect detected, the time of its onset, and the
degree of reversibility over time. Since data are accumulated continu-
ously over time using the telemetry-based systems, there are a variety
of data analysis approaches dependent upon how one chooses to subdi-
vide the data over time. For graphic representation, most laboratories
have used a 5–10 min mean value calculation over the 24 h of data
collection. This type of analysis gives a rather high level of detail for
time-dependent effects but can have a higher degree of variability
merely based on the short time intervals. The statistical analysis of this
type of data set can also lead to spurious effects for a given point in
time. Therefore, for statistical analysis, larger time intervals are typically
selected, extending to the extreme case of deﬁning super-intervals that
can extend for over an hour or more, and are selected to compare pos-
sible drug-induced effects over the time period during which the
effects appear to be largest by visual inspection (Sivarajah et al.,
2010). In most cases one would anticipate the largest effects to be asso-
ciated with the time of maximal drug concentration tmax. However,
there are situations in which there may not be a direct correlation be-
tween the plasma levels of a given test article and the resultant hemo-
dynamic effects seen, such as with cases where metabolites may play
an important role in hemodynamic effects observed. In these cases,
the deﬁning of super-intervals based on the observed effects, as op-
posed to the timing of the plasma drug levels is advantageous in de-
scribing the drug-induced effects. Finally, as mentioned above,
deﬁning the super-intervals to exclude times in which the animals are
excited for reasons other than drug-induced effects can be used effec-
tively in the data evaluation. For example, in the studies conducted
with amrinone the animals had blood drawn 4 h post-dosing and
were fed at 7 h post-dosing. The super-intervals selected for evaluation
(0.5–3.5, 5–6.5 and 8–13.5 h post-dosing) speciﬁcally excluded these
times thereby eliminating these potential artifacts from the analysis.
5. Conclusion
In this ﬁrst report coming from a HESI-based consortium focusing
on drug-induced effects on myocardial contractility, LVdP/dtmax was
shown to be a useful parameter to detect effects in the conscious, chron-
ically instrumented dog across 6 of the participating laboratories. Using
this experimental approach, all laboratories could identify the inotropic
effect of the test agents and these effects could be correlated to the plasma
drug levelsmeasured in the same studies. These, in turn, appear to be very
similar to the plasma drug levels in man shown to have inotropic effects
with their clinical use, thereby establishing a good translation between
the preclinical and clinical settings.
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